Vedolizumab prevented the postoperative recurrence of Crohn’s disease and should be considered a prophylactic treatment in ...

15, 2024 — Scientists uncovered an overlooked mechanism in the gut immune system of patients suffering from severe cases of Crohn's disease. The discovery may help define how to treat patients ...

For many people with Crohn’s disease, reaching remission—when inflammation is no longer detectable—seems like a major victory ...

A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn's disease, a new ...

A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn’s disease.A new ...

Crohn’s disease is a type of inflammatory bowl disease (IBD) that can take place anywhere in the digestive tract. According to the Centers for Disease Control and Prevention (CDC), prevalence of IBD ...

MetroCreative Inflammatory bowel disease (IBD) affects between 2.4 and 3.1 million people across the United States, according ...

Lutikizumab is under clinical development by AbbVie and currently in Phase II for Crohn's Disease (Regional Enteritis).

Managing inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, may soon become more advanced and ...

Risk factors for postoperative disease recurrence help guide the physician in determining the appropriate treatment strategy after Crohn's disease surgery. The approach to Crohn's disease ...

Crohn disease is a chronic condition characterised by intestinal inflammation and progressive bowel damage associated with impaired functioning. In rheumatoid arthritis, which shares some common ...